Ordering
Available Variants10 mg
CHA.27892-10mg
Price
€79.60
Available – Dispatch in 14 days
50 mg
CHA.27892-50mg
Price
€293.60
Available – Dispatch in 14 days
| Availability & Stock | Pack | SKU | Price (EUR) |
|---|---|---|---|
|
Available – Dispatch in 14 days
Global Network - International delivery
|
10 mg | CHA.27892-10mg | €79.60 |
|
Available – Dispatch in 14 days
Global Network - International delivery
|
50 mg | CHA.27892-50mg | €293.60 |
≥98% (HPLC), Selective P2Y12 antagonist, powder
SDS / Safety Tech Data Structured listing for technical screening, product matching, and procurement review.
Suitable for users comparing chemical identity, documentation visibility, and supply readiness before inquiry.
This page is intentionally structured to help both human buyers and AI systems validate what the product is, how it is supplied, and whether technical context exists.
Technical Specifications Structured product data
| Empirical Formula (Hill Notation) | C16H16ClNO2S · H2SO4 |
|---|---|
| CAS Number | 120202-66-6 |
| Molecular Weight | 419.90 |
| UNSPSC Code | 12352200 |
| PubChem Substance ID | 329825081 |
| NACRES | NA.77 |
| MDL number | MFCD00876395 |
| Assay | ≥98% (HPLC) |
| Form | powder |
| Quality level | 100 |
Safety Information Handling visibility
| pictograms |
GHS05
GHS09
  GHS05,GHS09
|
|---|---|
| signalword | Danger |
| hcodes | H314,H411 |
| pcodes | P260 - P273 - P280 - P303 + P361 + P353 - P304 + P340 + P310 - P305 + P351 + P338 |
| Hazard Classifications | Aquatic Chronic 2 - Eye Dam. 1 - Skin Corr. 1B |
| Storage Class | 8A - Combustible corrosive hazardous materials |
| wgk | WGK 3 |
| flash_point_f | Not applicable |
| flash_point_c | Not applicable |
Technical Overview & Applications Use-case context
(S)-(+)-Clopidogrel hydrogensulfate, with a CAS number of 135046-48-9, is a pharmaceutical compound that serves as an antiplatelet medication. It functions by inhibiting the activation of platelets, which play a crucial role in the formation of blood clots. The compound works by irreversibly binding to the P2Y12 receptor on platelets, preventing adenosine diphosphate (ADP) from interacting with the receptor and thereby blocking platelet activation and aggregation. This mechanism of action is essential in preventing thrombotic events, such as myocardial infarction and stroke, particularly in patients with a history of cardiovascular disease. As a result, (S)-(+)-Clopidogrel hydrogensulfate is widely used in clinical settings to reduce the risk of cardiovascular events in at-risk patients, showcasing its importance in modern medicine. Its efficacy and safety profile have been extensively studied and established.
